M
Marco Valgimigli
Researcher at University of Bern
Publications - 772
Citations - 91095
Marco Valgimigli is an academic researcher from University of Bern. The author has contributed to research in topics: Percutaneous coronary intervention & Myocardial infarction. The author has an hindex of 105, co-authored 696 publications receiving 69184 citations. Previous affiliations of Marco Valgimigli include University of Düsseldorf & Erasmus University Medical Center.
Papers
More filters
Journal ArticleDOI
The impact of the COVID-19 pandemic upon patients, staff, and on the future practices of percutaneous coronary intervention
TL;DR: The COVID pandemic in 2020 had unpredictable consequences on the presentation and management of patients with ischaemic heart disease as mentioned in this paper, and it is clear that there are new opportunities for optimising patient management pathways and in particular enhanced use of information technology.
Journal ArticleDOI
Comparative effects of fentanyl versus morphine on platelet inhibition induced by ticagrelor in patients with ST-segment elevation myocardial infarction: Full results of the PERSEUS randomized trial
Juan F. Iglesias,Marco Valgimigli,Federico Carbone,Nathalie Lauriers,Pier Giorgio Masci,Sophie Degrauwe +5 more
TL;DR: In patients with STEMI undergoing primary PCI, fentanyl did not improve platelet inhibition at 2 hours after ticagrelor pre-treatment compared with morphine, and Fentanyl may, however, accelerate ticAGrelor absorption and increase platelets inhibition at 4 hours compared to morphine.
Journal ArticleDOI
Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.
Nicolas M. Van Mieghem,Martin Unverdorben,Christian Hengstenberg,Helge Möllmann,Roxana Mehran,Diego López-Otero,Luis Nombela-Franco,Raul Moreno,Peter Nordbeck,Holger Thiele,Irene Lang,José Luis Zamorano,Fayaz A. Shawl,Masanori Yamamoto,Yusuke Watanabe,Kentaro Hayashida,Rainer Hambrecht,Felix Meincke,Pascal Vranckx,James Jin,Eric Boersma,Josep Rodés-Cabau,Patrick Ohlmann,Piera Capranzano,Hyo-Soo Kim,Thomas Pilgrim,Richard A. Anderson,Usman Baber,Anil Duggal,Petra Laeis,Hans Lanz,Cathy Chen,Marco Valgimigli,Roland Veltkamp,Shigeru Saito,George Dangas,Envisage-Tavi Af Investigators +36 more
TL;DR: The role of direct oral anticoagulants as compared with vitamin K antagonists for atrial fibrillation after successful transcatheter aortic-valve replacement (TAVR) has not been well studied as discussed by the authors.
Journal ArticleDOI
'Ten Commandments' of the 2017 ESC DAPT focused update Guidelines.
TL;DR: A gene therapy with just one gene (a transcription factor named Tbx18) suffices to perform this little feat of biological alchemy and it is conceivable that, eventually, biological pacemakers might supplant electronic devices for more common indications.